Auf dieser Seite
ALT Altimmune, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 12, 2026
$2,74
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$2,5652-Wochen-Tief
$6,4452-Wochen-Hoch
Marktkapitalisierung (MRQ)
$532M
P/E
-2.7
EPS
$-1.00
Umsatz
$41.0K
Ihre Abzeichen
52W-Spanne
$3–$6
Analystenbewertung
BUY
Kursziel
$17
P/E
-2.7
ROE
-45.6%
Nettogewinnmarge
-214861.0%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
ALT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$2.73
Marktkapitalisierung (MRQ)
$532M
P/E
-2.7
EPS
$-1.00
Umsatz
$41.0K
ROE
-45.6%
Verschuldungsgrad (MRQ)
0.1
52W-Spanne
$3–$6
ALT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 14. September 2018 | 1-for-30 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$41.0K2016-12-31 → 2025-12-31
EPS$-1.002016-12-31 → 2025-12-31
Freier Cashflow$-68M2016-12-31 → 2025-12-31
Nettogewinnmarge-214861.0%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | ALT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -2.75-Jahres-Durchschnitt ≈-5.8 | ≈-5.8 | · | · | |
| P/S | 7396.75-Jahres-Durchschnitt ≈5179.2 | ≈5179.2 | 144.0 | Überbewertet | |
| K/B (MRQ) | 1.15-Jahres-Durchschnitt ≈3.3 | ≈3.3 | 3.1 | Unterbewertet | |
| EV / EBITDA | -0.75-Jahres-Durchschnitt ≈-3.6 | ≈-3.6 | · | · | |
| Kurs / FCF (TTM) | -6.95-Jahres-Durchschnitt ≈-8.4 | ≈-8.4 | · | · | |
| Kurs / Cashflow (TTM) | -7.05-Jahres-Durchschnitt ≈-8.1 | ≈-8.1 | · | · | |
| EV / Revenue (EV / Umsatz) | 1563.35-Jahres-Durchschnitt ≈-1759.5 | ≈-1759.5 | · | · | |
| EV / FCF (TTM) | -3.15-Jahres-Durchschnitt ≈-4.8 | ≈-4.8 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 1.35-Jahres-Durchschnitt ≈3.4 | ≈3.4 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | ALT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Operating Margin (Betriebsgewinnmarge) | -230461.0%5-Jahres-Durchschnitt ≈-128401.5% | ≈-128401.5% | -2083.6% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -230461.0%5-Jahres-Durchschnitt ≈-128338.7% | ≈-128338.7% | -2083.6% | Schwach | |
| Pretax Margin (Vorgewinnmarge) | -216522.0%5-Jahres-Durchschnitt ≈-117982.6% | ≈-117982.6% | -8123.7% | Schwach | |
| Net Profit Margin (Nettogewinnmarge) | -214861.0%5-Jahres-Durchschnitt ≈-117708.3% | ≈-117708.3% | -1978.2% | Schwach | |
| ROA | -42.0%5-Jahres-Durchschnitt ≈-44.1% | ≈-44.1% | -38.2% | Schwach | |
| ROE | -45.6%5-Jahres-Durchschnitt ≈-52.4% | ≈-52.4% | -43.9% | Im Einklang | |
| ROIC | -36.2% | · | -36.2% | Im Einklang |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | ALT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.15-Jahres-Durchschnitt ≈0.1 | ≈0.1 | · | · | |
| Liquiditätsgrad (MRQ) | 26.85-Jahres-Durchschnitt ≈14.3 | ≈14.3 | 13.8 | Starke Liquidität | |
| Quick Ratio | 18.25-Jahres-Durchschnitt ≈13.7 | ≈13.7 | 7.0 | Starke Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.15-Jahres-Durchschnitt ≈0.1 | ≈0.1 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | ALT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 105.0%5-Jahres-Durchschnitt ≈-12.1% | ≈-12.1% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -83.5% | · | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | -65.3% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | ALT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.0 | ≈0.0 | 0.0 | Im Einklang | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$719.30 | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
17.3%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 12, 2026 | $-0.12 | $-0.14 | 14.2% |
| 31. März 2026 | Mai 13, 2026 | $-0.18 | $-0.25 | 27.4% |
| 31. Dezember 2025 | $-0.27 | $-0.25 | -10.2% | |
| 30. September 2025 | $-0.21 | $-0.28 | 26.1% | |
| 30. Juni 2025 | $-0.27 | $-0.33 | 17.2% | |
| 31. März 2025 | $-0.26 | $-0.37 | 29.1% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.0K | $20.0K | $426.0K | $-68.0K | $4M | $8M | $6M | $10M | $11M | $3M | · | · | |
| R&D Expense | $66M | $82M | $66M | $71M | $75M | $50M | $18M | $18M | $18M | $7M | $5M | $9M | |
| SG&A Expense | $28M | $21M | $18M | $17M | $15M | $13M | $9M | $10M | $8M | $7M | $6M | $11M | |
| Operating Expenses | $95M | $103M | $96M | $88M | $101M | $63M | $27M | $53M | $63M | $14M | $14M | $20M | |
| Operating Income | $-94M | $-103M | $-96M | $-88M | $-97M | $-55M | $-21M | $-43M | $-52M | $-11M | $-3M | $-10M | |
| Interest Expense | · | · | $35.0K | $8.0K | $5.0K | $9.4K | $2.2K | $297.1K | $162.1K | $38.5K | $54.6K | $210.4K | |
| Interest Income | $8M | $8M | $7M | $3M | $203.0K | $322.5K | $843.4K | $226.6K | $47.6K | $1.0K | · | · | |
| Other Non-op | $-190.0K | $48.0K | $166.0K | $-32.0K | $-374.0K | $24.1K | $15.1K | $277.9K | $5.7K | $42.3K | $8.1K | $-762 | |
| Pretax Income | $-89M | $-95M | $-88M | $-85M | $-97M | $-54M | $-21M | $-45M | $-52M | $-11M | $-3M | $-10M | |
| Income Tax | $-681.0K | · | · | $-197.0K | · | $-5M | $-58.5K | $-6M | $-6M | $0 | $61.7K | $61.7K | |
| Net Income | $-88M | $-95M | $-88M | $-85M | $-97M | $-49M | $-21M | $-39M | $-46M | $-11M | $-3M | $-10M | |
| EPS (Basic) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | · | · | · | $2.97 | $-0.05 | $-0.17 | |
| EPS (Diluted) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | · | · | · | $2.95 | $-0.05 | $-0.17 | |
| Shares (Basic) | 88,104,132 | 71,003,399 | 53,246,937 | 46,926,349 | 41,283,498 | 25,637,023 | · | · | · | 65,306,962 | 63,986,013 | 57,535,325 | |
| Shares (Diluted) | 88,104,132 | 71,003,399 | 53,246,937 | 46,926,349 | 41,283,498 | 25,637,023 | · | · | · | 65,657,802 | 63,986,013 | 57,535,325 | |
| EBITDA | $-94M | $-103M | $-96M | $-88M | $-96M | $-55M | $-21M | $-43M | · | $-11M | $-3M | $-10M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $44M | $37M | $135M | $111M | $190M | $116M | $9M | $34M | $9M | $3M | $16M | $19M | |
| Short-term Investments | $230M | $95M | $63M | $74M | · | $100M | $28M | · | · | $67M | $0 | · | |
| Receivables | · | · | · | · | · | · | · | · | · | · | · | $400.0K | |
| Prepaid Expense | $3M | $2M | $7M | $5M | $8M | $2M | $470.2K | $548.1K | $994.3K | $420.4K | $181.7K | $199.2K | |
| Current Assets | $278M | $137M | $210M | $193M | $204M | $230M | $39M | $39M | $23M | $4M | $17M | $19M | |
| PP&E (Net) | $312.0K | $413.0K | $651.0K | $1M | $1M | $1M | $1M | $1M | $603.1K | $177.9K | $233.7K | $325.8K | |
| PP&E (Gross) | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $2M | $3M | |
| Accum. Depreciation | $2M | $2M | $2M | $1M | $2M | $2M | $1M | $1M | $951.8K | $905.3K | $2M | $2M | |
| Goodwill | · | · | · | · | · | · | $0 | $0 | · | $19M | $22M | $2M | |
| Intangibles | · | $0 | $0 | $12M | $12M | $13M | $13M | $14M | $39M | $15M | · | · | |
| Other Non-current Assets | $1M | $2M | $363.0K | $615.0K | $872.0K | $977.2K | $128.5K | $183.7K | $238.9K | $22.2K | $53.4K | $53.4K | |
| Total Assets | $280M | $139M | $211M | $207M | $219M | $245M | $54M | $55M | $63M | $38M | $20M | $22M | |
| Accounts Payable | $3M | $211.0K | $2M | $5M | $2M | $612.3K | $18.2K | $372.9K | $129.1K | $2M | $521.1K | $391.4K | |
| Accrued Liabilities | · | · | · | · | · | $11M | $4M | $4M | $4M | $3M | · | · | |
| Short-term Debt | · | · | · | · | · | · | · | $71.6K | $49.7K | $458.6K | · | · | |
| Current Liabilities | $15M | $10M | $12M | $17M | $18M | $12M | $4M | $5M | $4M | $5M | $2M | $3M | |
| Capital Leases | $1M | $1M | $175.0K | $672.0K | $1M | $1M | $1M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $58.5K | $6M | $442.6K | $380.8K | $319.0K | |
| Other Non-current Liabilities | $6M | $5M | $40.0K | $60.0K | $80.0K | $110.3K | $130.2K | $140.1K | $160.0K | $442.6K | $433.4K | $493.1K | |
| Total Liabilities | $55M | $16M | $17M | $22M | $20M | $19M | $9M | $6M | $14M | $6M | $3M | $4M | |
| Long-term Debt | $34M | · | · | · | · | · | · | $500.0K | $500.0K | $526.0K | · | · | |
| Total Debt | $34M | · | · | $5M | $1M | $2M | $2M | $71.6K | · | · | $0 | $746.1K | |
| Common Stock | $11.0K | $7.0K | $7.0K | $5.0K | $4.0K | $3.7K | $1.5K | $876 | $61 | $692 | $6.4K | $6.4K | |
| Paid-in Capital | $879M | $690M | $665M | $568M | $497M | $417M | $188M | $170M | $122M | $71M | $240M | $239M | |
| Retained Earnings | $-649M | $-561M | $-466M | $-378M | $-293M | $-186M | $-137M | $-117M | $-78M | $-31M | $-224M | $-220M | |
| AOCI | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-8M | $0 | $-229.5K | |
| Stockholders' Equity | $225M | $124M | $194M | $185M | $199M | $226M | $46M | $48M | $39M | $32M | $43M | $18M | |
| Liabilities + Equity | $280M | $139M | $211M | $207M | $219M | $245M | $54M | $55M | $63M | $38M | $20M | $22M | |
| Shares Outstanding | 110,882,735 | 72,352,701 | 70,677,400 | 49,199,845 | 40,993,768 | 37,142,946 | 15,312,167 | 9,078,238 | 608,499 | 6,917,204 | 64,382,086 | 63,603,303 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | $-205.0K | $551.0K | $428.9K | $387.3K | · | · | · | · | · | |
| Stock-based Comp | $16M | $14M | $11M | $8M | $6M | $3M | $1M | $773.2K | $1M | $965.4K | $613.0K | $2M | |
| Deferred Tax | $-681.0K | · | · | · | · | · | $-58.5K | $-6M | $-3M | $61.8K | $61.7K | $61.7K | |
| Restructuring | · | · | · | · | · | · | · | · | · | $0 | $3M | $0 | |
| Other Non-cash | · | · | · | $14M | $13M | $12M | · | · | · | · | · | · | |
| Operating Cash Flow | $-68M | $-80M | $-76M | $-63M | $-78M | $-34M | $-10M | $-9M | $-20M | $-6M | $-3M | $-8M | |
| CapEx | $11.0K | · | $47.0K | $126.0K | $12M | $204.0K | $1.2K | $975.4K | $112.4K | $125.0K | $86.5K | $92.3K | |
| Investing Cash Flow | $-132M | $-28M | $14M | $-73M | $88M | $-72M | $-28M | $-1M | $14M | · | · | · | |
| Debt Issued | $35M | · | · | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $35M | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $174M | $10M | $87M | $56M | $65M | $48M | · | $4M | · | $4M | $973.1K | $18M | |
| Net Stock Activity | $174M | $10M | $87M | $56M | $65M | $48M | · | $4M | · | $4M | $973.1K | $18M | |
| Financing Cash Flow | $207M | $10M | $86M | $57M | $65M | $213M | $13M | $32M | $16M | · | · | · | |
| Net Change in Cash | $7M | $-98M | $24M | $-79M | $74M | $107M | $-25M | $22M | $9M | $138M | $-3M | $8M | |
| Free Cash Flow | $-68M | · | $-76M | $-63M | $-90M | $-35M | $-10M | $-10M | · | $201M | $-3M | $-9M | |
| Levered FCF | · | · | · | $-63M | · | $-35M | $-10M | $-11M | · | · | $-3M | $-9M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -230461.0% | -515860.0% | -22518.5% | 129029.4% | -2197.4% | -669.5% | -370.0% | -414.6% | · | -6699.0% | · | · | |
| Net Margin | -214861.0% | -475295.0% | -20762.2% | 124577.9% | -2201.4% | -599.2% | -353.7% | -379.2% | · | 115286.4% | · | · | |
| Pretax Margin | -216522.0% | -475295.0% | -20762.2% | 124867.7% | -2201.4% | -665.4% | -354.7% | -438.7% | · | 121929.0% | · | · | |
| EBITDA Margin | -230461.0% | -515860.0% | -22518.5% | 129330.9% | -2184.9% | -665.9% | -370.0% | -414.6% | · | -6699.0% | · | · | |
| ROA | -42.0% | -54.3% | -42.4% | -39.8% | -41.9% | -32.8% | -37.7% | -66.5% | · | 158.5% | -16.4% | -50.9% | |
| ROE | -45.6% | -74.0% | -51.3% | -43.4% | -47.5% | -23.1% | -43.2% | -89.0% | · | 619.4% | -19.7% | -77.8% | |
| ROIC | -36.2% | · | · | -46.1% | · | -21.7% | -45.2% | -76.5% | · | -54.7% | -20.8% | -53.9% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.5 | 13.1 | 17.3 | 11.3 | 11.2 | 19.2 | 10.0 | 8.7 | · | 1.1 | 7.9 | 7.5 | |
| Quick Ratio | 18.2 | 12.6 | 16.3 | 10.8 | 10.4 | 18.0 | 9.5 | 7.4 | · | 1.1 | 7.1 | 7.4 | |
| Debt / Equity | 0.2 | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | 0.0 | 0.0 | |
| LT Debt / Equity | 0.2 | · | · | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | |
| Interest Coverage | · | · | -2740.8 | -10967.5 | -17134.7 | -5816.7 | -9565.5 | -144.2 | · | · | -62.3 | -48.4 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | -0.0 | 0.0 | 0.1 | 0.1 | 0.2 | · | 0.0 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.03 | $1.71 | $2.75 | $3.77 | $4.86 | $6.08 | $2.97 | $5.32 | · | $0.29 | $0.26 | $0.29 | |
| Revenue / Share | $0.00 | $0.00 | $0.01 | $-0.00 | $0.11 | · | · | · | · | $0.00 | · | · | |
| Cash Flow / Share | $-0.77 | $-1.12 | $-1.42 | $-1.33 | $-1.90 | · | · | · | · | $3.07 | · | · | |
| Cash / Share | $0.39 | $0.51 | $1.91 | $2.26 | $4.64 | $3.12 | $0.59 | $3.71 | · | $2.27 | $0.24 | $0.29 | |
| EPS (TTM) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | $2.92 | $2.92 | $2.92 | $2.95 | $-0.05 | $-0.17 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 105.0% | -95.3% | · | · | -46.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | · | -83.5% | -62.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -65.3% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41.0K | $20.0K | $426.0K | $-68.0K | $4M | $8M | $6M | $10M | $11M | $3M | · | · | |
| Net Income TTM | $-88M | $-95M | $-88M | $-85M | $-97M | $-49M | $-21M | $-39M | $-46M | $-11M | $-3M | $-10M | |
| Market Cap | $400M | $522M | $795M | $809M | $376M | $419M | $29M | $19M | · | · | · | · | |
| Enterprise Value | $161M | · | · | $629M | $187M | $205M | $-6M | $-15M | · | · | · | · | |
| P/E | -3.6 | -5.4 | -6.8 | -9.1 | -3.9 | -5.9 | 0.6 | 0.7 | 20.4 | · | · | · | |
| P/S | 9763.1 | 26083.1 | 1866.5 | -11902.0 | 85.1 | 51.2 | 5.0 | 1.8 | · | · | · | · | |
| P/B | 1.8 | 4.2 | 4.1 | 4.4 | 1.9 | 1.9 | 0.6 | 0.4 | · | · | · | · | |
| P / Tangible Book | 1.8 | 4.2 | 4.1 | 4.7 | 2.0 | 2.0 | · | · | · | · | · | · | |
| P / Cash Flow | -5.9 | -6.5 | -10.5 | -12.9 | -4.8 | -12.2 | -3.0 | -2.0 | · | · | · | · | |
| P / FCF | -5.9 | · | -10.5 | -12.9 | -4.2 | -12.1 | -3.0 | -1.8 | · | · | · | · | |
| EV / EBITDA | -1.7 | · | · | -7.2 | -1.9 | -3.8 | 0.3 | 0.3 | · | · | · | · | |
| EV / FCF | -2.4 | · | · | -10.0 | -2.1 | -5.9 | 0.7 | 1.4 | · | · | · | · | |
| EV / Revenue | 3929.7 | · | · | -9250.6 | 42.3 | 25.0 | -1.1 | -1.4 | · | · | · | · | |
| Earnings Yield | -27.7% | -18.6% | -14.8% | -11.0% | -25.7% | -16.9% | 154.5% | 141.8% | 4.9% | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $26.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $37.0K | $362.0K | $6.0K | $21.0K | $-110.0K | $2.0K | |
| R&D Expense | $19M | $16M | $18M | $15M | $17M | $16M | $20M | $20M | $21M | $21M | $17M | $18M | $13M | $17M | $19M | $20M | |
| SG&A Expense | $8M | $8M | $11M | $6M | $6M | $6M | $5M | $5M | $6M | $5M | $4M | $5M | $5M | $5M | $4M | $4M | |
| Operating Expenses | $26M | $24M | $29M | $21M | $23M | $22M | $25M | $25M | $27M | $27M | $34M | $23M | $18M | $22M | $23M | $25M | |
| Operating Income | $-26M | $-24M | $-29M | $-21M | $-23M | $-22M | $-25M | $-25M | $-27M | $-27M | $-34M | $-23M | $-18M | $-22M | $-23M | $-25M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1.0K | · | $29.0K | $2.0K | $2.0K | $-183.0K | $64.0K | |
| Interest Income | $5M | $3M | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | |
| Other Non-op | $-25.0K | $-152.0K | $-27.0K | $-86.0K | $-92.0K | $15.0K | $118.0K | $18.0K | $-76.0K | $-12.0K | $20.0K | $14.0K | $113.0K | $19.0K | $-217.0K | $50.0K | |
| Pretax Income | $-23M | $-23M | $-27M | $-19M | $-22M | $-20M | $-23M | $-23M | $-25M | $-24M | $-32M | $-21M | · | · | $-22M | $-24M | |
| Income Tax | · | · | $0 | $0 | $0 | $-681.0K | · | $0 | $0 | $0 | · | $0 | $0 | $0 | $0 | $-197.0K | |
| Net Income | $-23M | $-23M | $-27M | $-19M | $-22M | $-20M | $-23M | $-23M | $-25M | $-24M | $-32M | $-21M | $-16M | $-20M | $-22M | $-24M | |
| EPS (Basic) | $-0.12 | $-0.18 | $-0.26 | $-0.21 | $-0.27 | $-0.26 | $-0.33 | $-0.32 | $-0.35 | $-0.34 | $-0.55 | $-0.39 | $-0.32 | $-0.40 | $-0.47 | $-0.48 | |
| EPS (Diluted) | $-0.12 | $-0.18 | $-0.26 | $-0.21 | $-0.27 | $-0.26 | $-0.33 | $-0.32 | $-0.35 | $-0.34 | $-0.55 | $-0.39 | $-0.32 | $-0.40 | $-0.47 | $-0.48 | |
| Shares (Basic) | 185,443,736 | 124,461,818 | · | 89,418,028 | 81,477,548 | 75,547,746 | · | 71,084,787 | 70,924,371 | 70,801,713 | · | 53,633,354 | 50,691,558 | 50,125,685 | · | 49,286,535 | |
| Shares (Diluted) | 185,443,736 | 124,461,818 | · | 89,418,028 | 81,477,548 | 75,547,746 | · | 71,084,787 | 70,924,371 | 70,801,713 | · | 53,633,354 | 50,691,558 | 50,125,685 | · | 49,286,535 | |
| EBITDA | $-26M | $-24M | · | $-21M | $-23M | $-22M | · | $-25M | $-27M | $-27M | · | $-23M | $-18M | $-22M | · | $-25M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63M | $98M | $44M | $61M | $183M | $49M | $37M | $31M | $57M | $79M | $135M | $87M | $102M | $105M | $111M | $127M | |
| Short-term Investments | $263M | $234M | $230M | $150M | · | $101M | $95M | $108M | $108M | $103M | $63M | $54M | $58M | $61M | $74M | $74M | |
| Prepaid Expense | $5M | $1M | $3M | $4M | $4M | $3M | $2M | $3M | $3M | $3M | $7M | $8M | $6M | $4M | $5M | $5M | |
| Current Assets | $335M | $335M | $278M | $217M | $188M | $155M | $137M | $146M | $171M | $188M | $210M | $153M | $170M | $173M | $193M | $211M | |
| PP&E (Net) | $60.0K | $208.0K | $312.0K | $337.0K | $364.0K | $384.0K | $413.0K | $446.0K | $483.0K | $544.0K | $651.0K | $765.0K | $882.0K | $1M | $1M | $1M | |
| PP&E (Gross) | · | · | $3M | · | · | · | $3M | · | · | · | $3M | · | · | · | $3M | · | |
| Accum. Depreciation | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $1M | · | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | · | $12M | |
| Other Non-current Assets | $90.0K | $746.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $299.0K | $363.0K | $425.0K | $483.0K | $546.0K | $615.0K | $682.0K | |
| Total Assets | $527M | $336M | $280M | $218M | $190M | $157M | $139M | $148M | $173M | $188M | $211M | $167M | $183M | $187M | $207M | $225M | |
| Accounts Payable | $1M | $2M | $3M | $5M | $851.0K | $1M | $211.0K | $1M | $3M | $4M | $2M | $3M | $4M | $5M | $5M | $1M | |
| Current Liabilities | $13M | $11M | $15M | $13M | $9M | $10M | $10M | $9M | $15M | $11M | $12M | $12M | $11M | $15M | $17M | $16M | |
| Capital Leases | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $44.0K | $175.0K | $303.0K | $429.0K | $552.0K | $672.0K | $788.0K | |
| Other Non-current Liabilities | $6M | $6M | $6M | $6M | $5M | $16.0K | $5M | $26.0K | $31.0K | $37.0K | $40.0K | $46.0K | $52.0K | $56.0K | $60.0K | $66.0K | |
| Total Liabilities | $53M | $52M | $55M | $33M | $29M | $15M | $16M | $14M | $21M | $15M | $17M | $16M | $16M | $19M | $22M | $20M | |
| Long-term Debt | $35M | $35M | $34M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $35M | $35M | · | $14M | $14M | · | · | · | · | · | · | $4M | $4M | $4M | · | $5M | |
| Common Stock | $19.0K | $13.0K | $11.0K | $10.0K | $9.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | |
| Paid-in Capital | $1.18B | $961M | $879M | $813M | $770M | $728M | $690M | $676M | $673M | $669M | $665M | $590M | $587M | $571M | $568M | $567M | |
| Retained Earnings | $-695M | $-672M | $-649M | $-622M | $-603M | $-581M | $-561M | $-538M | $-515M | $-491M | $-466M | $-435M | $-414M | $-398M | $-378M | $-356M | |
| AOCI | $-6M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | |
| Stockholders' Equity | $474M | $284M | $225M | $186M | $161M | $142M | $124M | $133M | $153M | $173M | $194M | $150M | $168M | $168M | $185M | $205M | |
| Liabilities + Equity | $527M | $336M | $280M | $218M | $190M | $157M | $139M | $148M | $173M | $188M | $211M | $167M | $183M | $187M | $207M | $225M | |
| Shares Outstanding | 194,474,154 | 130,221,154 | 110,882,735 | 95,598,665 | 85,076,300 | 77,825,450 | 72,352,701 | 71,124,407 | 71,046,267 | 70,899,134 | 70,677,400 | 52,858,920 | 52,657,661 | 49,286,710 | 49,199,845 | 49,161,637 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $-552.0K | $-505.0K | $-356.0K | · | $-141.0K | |
| Stock-based Comp | $3M | $3M | $5M | $4M | $4M | $4M | $3M | $3M | $4M | $4M | $2M | $3M | $3M | $3M | $2M | $2M | |
| Deferred Tax | · | · | $0 | $0 | $0 | $-681.0K | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | · | $-2M | · | · | |
| Operating Cash Flow | $-24M | $-21M | $-19M | $-12M | $-19M | $-17M | $-18M | $-27M | $-18M | $-16M | $-17M | $-20M | $-19M | $-19M | $-17M | $-15M | |
| CapEx | $32.0K | $21.0K | $1.0K | $0 | · | · | · | · | · | · | $0 | $0 | $-4.0K | $51.0K | $38.0K | $60.0K | |
| Investing Cash Flow | $-221M | $-4M | $-79M | $-149M | $101M | $-5M | $14M | $1M | $-4M | $-40M | $-8M | $4M | $4M | $13M | $981.0K | $-25M | |
| Debt Issued | · | · | $20M | $0 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $-89.0K | $9M | $62M | $40M | $38M | $35M | · | · | · | · | $73M | $510.0K | · | · | $0 | $32M | |
| Net Stock Activity | · | $9M | · | · | · | $35M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $211M | $78M | $81M | $39M | $52M | $34M | $10M | $266.0K | $-46.0K | $-261.0K | $73M | $588.0K | $13M | $-302.0K | $-43.0K | $32M | |
| Net Change in Cash | $-35M | $54M | $-17M | $-122M | $134M | $12M | $5M | $-26M | $-22M | $-56M | $48M | $-15M | $-2M | $-6M | $-16M | $-8M | |
| Free Cash Flow | · | $-21M | · | · | · | · | · | · | · | · | · | · | · | $-19M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -417180.0% | -458440.0% | -436300.0% | · | -495340.0% | -534900.0% | -535880.0% | · | -6226.5% | -300116.7% | -103614.3% | · | -1237600.0% | |
| Net Margin | · | · | · | -380280.0% | -442920.0% | -391500.0% | · | -456900.0% | -492800.0% | -487880.0% | · | -5710.2% | -267683.3% | -95590.5% | · | -1175800.0% | |
| Pretax Margin | · | · | · | -380280.0% | -442920.0% | -405120.0% | · | · | · | · | · | -5710.2% | · | · | · | -1185650.0% | |
| EBITDA Margin | · | · | · | -417180.0% | -458440.0% | -436300.0% | · | -495340.0% | -534900.0% | -535880.0% | · | -6226.5% | -300116.7% | -105309.5% | · | -1237600.0% | |
| ROA | -6.4% | -9.2% | · | -10.4% | -12.2% | -11.3% | · | -14.5% | -13.8% | -13.0% | · | -10.5% | -8.2% | -10.2% | · | -10.2% | |
| ROE | -7.2% | -10.6% | · | -11.9% | -14.1% | -12.4% | · | -16.1% | -15.4% | -14.3% | · | -11.6% | -8.9% | -11.4% | · | -11.3% | |
| ROIC | · | · | · | · | · | -14.8% | · | · | · | · | · | · | · | · | · | -11.7% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 26.8 | 29.6 | · | 17.2 | 20.4 | 15.8 | · | 16.9 | 11.3 | 16.5 | · | 12.9 | 14.8 | 11.6 | · | 13.4 | |
| Quick Ratio | 26.1 | 29.3 | · | 16.7 | 19.9 | 15.3 | · | 16.1 | 10.9 | 16.1 | · | 11.9 | 14.0 | 11.1 | · | 12.8 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -26794.0 | · | -777.2 | -9003.5 | -10879.5 | · | -386.8 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.44 | $2.18 | · | $1.94 | $1.90 | $1.83 | · | $1.88 | $2.15 | $2.44 | · | $2.85 | $3.19 | $3.40 | · | $4.17 | |
| Revenue / Share | · | · | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.01 | $0.00 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-0.17 | · | · | · | $-0.22 | · | · | · | $-0.23 | · | · | · | $-0.39 | · | · | |
| Cash / Share | $0.32 | $0.75 | · | $0.64 | $2.15 | $0.63 | · | $0.44 | $0.80 | $1.11 | · | $1.64 | $1.94 | $2.12 | · | $2.59 | |
| EPS (TTM) | $-0.77 | $-0.92 | · | $-1.07 | $-1.18 | $-1.26 | · | $-1.56 | $-1.63 | $-1.60 | · | $-1.58 | $-1.67 | $-1.77 | · | $-1.90 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41.0K | $41.0K | · | $20.0K | $20.0K | $20.0K | · | $52.0K | $409.0K | $410.0K | · | $279.0K | $-81.0K | $-79.0K | · | $3M | |
| Net Income TTM | $-92M | $-91M | · | $-84M | $-88M | $-90M | · | $-104M | $-101M | $-93M | · | $-78M | $-81M | $-85M | · | $-87M | |
| Market Cap | $591M | $401M | · | $360M | $329M | $389M | · | $437M | $472M | $722M | · | $137M | $186M | $208M | · | $628M | |
| Enterprise Value | $300M | $104M | · | $164M | $160M | · | · | · | · | · | · | $959.2K | $30M | $47M | · | $430M | |
| P/E | -3.9 | -3.3 | · | -3.5 | -3.3 | -4.0 | · | -3.9 | -4.1 | -6.4 | · | -1.6 | -2.1 | -2.4 | · | -6.7 | |
| P/S | 14419.5 | 9782.5 | · | 18020.3 | 16462.3 | 19456.4 | · | 8398.2 | 1155.2 | 1760.4 | · | 492.6 | -2294.8 | -2632.8 | · | 189.2 | |
| P/B | 1.2 | 1.4 | · | 1.9 | 2.0 | 2.7 | · | 3.3 | 3.1 | 4.2 | · | 0.9 | 1.1 | 1.2 | · | 3.1 | |
| P / Tangible Book | 1.2 | 1.4 | · | 1.9 | 2.0 | 2.7 | · | 3.3 | 3.1 | 4.2 | · | 0.9 | 1.1 | 1.2 | · | 3.3 | |
| P / Cash Flow | · | -19.2 | · | · | · | -23.1 | · | · | · | -44.1 | · | · | · | -10.7 | · | · | |
| EV / Revenue | 7308.8 | 2537.7 | · | 8203.8 | 8023.6 | · | · | · | · | · | · | 3.4 | -371.5 | -590.6 | · | 129.7 | |
| Earnings Yield | -25.3% | -29.9% | · | -28.4% | -30.5% | -25.2% | · | -25.4% | -24.5% | -15.7% | · | -60.8% | -47.3% | -41.9% | · | -14.9% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $41.0K | $20.0K | $426.0K | $-68.0K | $4M |
| Betriebsgewinnmarge % | -230461.0% | -515860.0% | -22518.5% | 129029.4% | -2197.4% |
| Nettoergebnis | $-88M | $-95M | $-88M | $-85M | $-97M |
| Verwässerte EPS | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.2 | · | · | 0.0 | 0.0 |
| Liquiditätsgrad | 18.5 | 13.1 | 17.3 | 11.3 | 11.2 |
| Quick Ratio | 18.2 | 12.6 | 16.3 | 10.8 | 10.4 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-68M | · | $-76M | $-63M | $-90M |
Institutionelle Eigentümer (13F) 235 Einreicher · $501.0M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
235
Gehaltener Wert
$501.0M
Neue Positionen
61
Geschlossene Positionen
17
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 61 (+31 vs. Vorquartal) | 17 (-16 vs. Vorquartal) | 87 (+3 vs. Vorquartal) | 37 (-2 vs. Vorquartal) | +81.8M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $61.971.264 | 20.385.284 | 12,37% | Aktien |
| Deep Track Capital, LP | $58.520.000 | 19.250.000 | 11,68% | Aktien |
| STATE STREET CORP | $36.779.562 | 12.098.540 | 7,34% | Aktien |
| VANGUARD GROUP INC | $34.263.084 | 9.491.159 | 6,84% | Aktien |
| TCG Crossover Management, LLC | $30.400.000 | 10.000.000 | 6,07% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $24.860.366 | 8.177.752 | 4,96% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $22.284.006 | 7.330.265 | 4,45% | Aktien |
| MARSHALL WACE, LLP | $20.796.808 | 6.841.055 | 4,15% | Aktien |
| VIKING GLOBAL INVESTORS LP | $20.368.000 | 6.700.000 | 4,07% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $19.760.000 | 6.500.000 | 3,94% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $15.238.163 | 5.011.314 | 3,04% | Aktien |
| Woodline Partners LP | $10.336.948 | 3.400.312 | 2,06% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $10.059.731 | 3.309.122 | 2,01% | Aktien |
| Trails Edge Capital Partners, LP | $8.086.400 | 2.660.000 | 1,61% | Aktien |
| Nuveen, LLC | $7.312.276 | 2.405.354 | 1,46% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $7.238.672 | 2.381.142 | 1,44% | Aktien |
| GOLDMAN SACHS GROUP INC | $6.731.928 | 2.214.450 | 1,34% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.469.872 | 1.799.300 | 1,09% | Kaufoption |
| GREAT POINT PARTNERS LLC | $5.293.345 | 1.741.232 | 1,06% | Aktien |
| NORTHERN TRUST CORP | $4.861.648 | 1.599.226 | 0,97% | Aktien |
| Weiss Asset Management LP | $4.653.641 | 1.530.803 | 0,93% | Aktien |
| Nantahala Capital Management, LLC | $4.560.000 | 1.500.000 | 0,91% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $3.930.723 | 1.293.001 | 0,78% | Aktien |
| Cormorant Asset Management, LP | $3.800.000 | 1.250.000 | 0,76% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $3.711.686 | 1.220.949 | 0,74% | Aktien |
| CITADEL ADVISORS LLC | $2.990.019 | 983.559 | 0,60% | Aktien |
| TWO SIGMA ADVISERS, LP | $2.865.979 | 793.900 | 0,57% | Aktien |
| UBS Group AG | $2.633.810 | 866.385 | 0,53% | Aktien |
| MORGAN STANLEY | $2.305.642 | 758.435 | 0,46% | Aktien |
| BANK OF AMERICA CORP /DE/ | $2.304.074 | 757.919 | 0,46% | Aktien |
| Ghisallo Capital Management LLC | $2.280.000 | 750.000 | 0,46% | Aktien |
| FMR LLC | $2.276.881 | 748.974 | 0,45% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2.222.477 | 731.078 | 0,44% | Aktien |
| Bank of New York Mellon Corp | $2.096.727 | 689.713 | 0,42% | Aktien |
| TANG CAPITAL MANAGEMENT LLC | $2.024.707 | 666.022 | 0,40% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $1.943.537 | 639.436 | 0,39% | Aktien |
| CITADEL ADVISORS LLC | $1.918.240 | 631.000 | 0,38% | Kaufoption |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.898.477 | 624.499 | 0,38% | Aktien |
| Point72 Asset Management, L.P. | $1.480.127 | 486.884 | 0,30% | Aktien |
| Rock Springs Capital Management LP | $1.433.254 | 471.465 | 0,29% | Aktien |
| Beirne Wealth Consulting Services, LLC | $1.282.449 | 421.858 | 0,26% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $1.277.712 | 420.300 | 0,26% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $1.128.375 | 371.176 | 0,23% | Aktien |
| BARCLAYS PLC | $1.068.825 | 351.587 | 0,21% | Aktien |
| Invesco Ltd. | $1.011.079 | 332.592 | 0,20% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $990.128 | 325.700 | 0,20% | Verkaufsoption |
| RHUMBLINE ADVISERS | $941.193 | 309.606 | 0,19% | Aktien |
| LMR Partners LLP | $912.000 | 300.000 | 0,18% | Aktien |
| CITIGROUP INC | $893.602 | 293.948 | 0,18% | Aktien |
| Steward Partners Investment Advisory, LLC | $810.680 | 266.671 | 0,16% | Aktien |
Aktivisten & 5%+-Eigentümer 18 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Shah, Nimish, Koh, Bong | 25. Juni 2020 | · | Erste Einreichung | Passive Anlage | SEC |
| Philip Hodges, Redmont Venture Partners, Inc., Redmont VAXN Capital Holdings, LLC, Paradigm Venture Partners, L.P. ×3 Einreichungen | 19. Oktober 2017 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 30. März 2016 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 12. Februar 2016 | · | Erste Einreichung | · | SEC |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C., PRESCOTT GROUP AGGRESSIVE SMALL CAP, L.P., PRESCOTT GROUP AGGRESSIVE SMALL CAP II, L.P., PHIL FROHLICH ×6 Einreichungen | 2. Dezember 2013 | · | Erste Einreichung | Passive Anlage | SEC |
| Theraclone Sciences, Inc. | 12. August 2013 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 27. Dezember 2010 | · | Erste Einreichung | Passive Anlage | SEC |
| Kelisia Holdings L imited, Panacea Biotec Limited | 18. September 2009 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 4. August 2009 | · | Erste Einreichung | Passive Anlage | SEC |
| HealthCare Ventures VII, L.P., HealthCare Partners VII, L.P., James H. Cavanaugh, Ph.D., John Littlechild, Harold Werner, Augustine Lawlor, Christopher Mirabelli, Ph.D. ×3 Einreichungen | 3. August 2009 | · | Erste Einreichung | Passive Anlage | SEC |
| Bear Stearns Health Innoventures, L.P., Bear Stearns Health Innoventures Offshore, L.P., BX, L.P., Bear Stearns Health Innoventures Employee Fund, L.P., BSHI Members, L.L.C., Bear Stearns Health Innoventures Management, L.L.C., Bear Stearns Asset Management Inc. ×3 Einreichungen | 29. Mai 2009 | · | Erste Einreichung | Vorstandskampagne | SEC |
| Integrated Core Strategies (US) LLC, Riverview Group LLC, Millennium Management LLC, Israel A. Englander ×2 Einreichungen | 23. April 2009 | · | Erste Einreichung | M&A / Verkauf | SEC |
| Nexia Biotechnologies Ltd. | 30. Mai 2008 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 17. August 2007 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 14. August 2007 | · | Erste Einreichung | Passive Anlage | SEC |
| MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG, MPM BioVentures III Parallel Fund, L.P., MPM Asset Management Investors 2004 BVIII LLC, MPM BioVentures III GP, L.P., MPM BioVentures III LLC, Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz, Kurt Wheeler | 14. August 2007 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 13. August 2007 | · | Erste Einreichung | M&A / Verkauf | SEC |
| QVT Financial LP, QVT Financial GP LLC ×2 Einreichungen | 7. August 2007 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 49 Insider · 26 Führungskräfte · 21 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jerome Benedict Durso | President and CEO | 13. August 2026 P | 62.500 | 4 | 0 | $213.775 |
| William Enright | President and CEO | 25. Mai 2018 P | 365.839 | 0 | 0 | $0 |
| David P Wright | President and CEO | 11. Dezember 2009 P | 399.500 | 0 | 0 | $0 |
| Gregory L Weaver | Chief Financial Officer | 31. Juli 2026 A | 39.831 | 2 | 0 | $49.200 |
| Andrew Shutterly | Acting Chief Financial Officer | 31. Juli 2024 A | 11.372 | 0 | 0 | $0 |
| Richard I Eisenstadt | Chief Financial Officer | 30. Januar 2024 M | 45.012 | 0 | 0 | $0 |
| William Michael Brown | Chief Financial Officer | 31. Juli 2021 A | 17.721 | 0 | 0 | $0 |
| Elizabeth Czerepak | CFO and EVP Corp. Development | 22. September 2017 A | · | 0 | 0 | $0 |
| MACNEILL PHILIP | VP, CFO, Treasurer, Secretary | 21. Dezember 2016 M | 126.346 | 0 | 0 | $0 |
| Linda L Chang | SVP, CFO & Secretary | 7. Januar 2015 M | 30.000 | 0 | 0 | $0 |
| Charles A. Reinhart III | SVP, Chief Financial Officer | 8. Dezember 2010 A | · | 0 | 0 | $0 |
| Kevin Price | President - PharmAthene UK,Ltd | 21. Januar 2009 A | 2.500 | 0 | 0 | $0 |
| Jeffrey Michael Jones | COO | 11. März 2015 A | 27.544 | 0 | 0 | $0 |
| Richard Thomas Menziuso | Principal Accounting Officer | 1. Oktober 2026 A | · | 0 | 0 | $0 |
| Linda M Richardson | Chief Commercial Officer | 16. September 2026 M | 17.174 | 0 | 0 | $0 |
| Scot M Roberts | Chief Scientific Officer | 31. Juli 2026 A | 113.699 | 0 | 0 | $0 |
| Raymond M Jordt | Chief Business Officer | 31. Januar 2026 A | 70.107 | 0 | 0 | $0 |
| Christophe Arbet-Engels | Chief Medical Officer | 1. Oktober 2025 A | · | 0 | 0 | $0 |
| Matthew Scott Harris | Chief Medical Officer | 31. Juli 2025 A | 16.087 | 0 | 0 | $0 |
| Sybil Tasker | Chief Medical Officer | 17. Juni 2019 A | · | 0 | 0 | $0 |
| Wayne Morges | SVP, Reg. Affairs & Quality | 8. Dezember 2014 A | 35.532 | 0 | 0 | $0 |
| Francesca M Cook | SVP, Policy & Gov't Affairs | 8. Dezember 2014 A | 37.631 | 0 | 0 | $0 |
| Thomas Richard Fuerst | EVP, Chief Scientific Officer | 1. Dezember 2011 A | 15.000 | 0 | 0 | $0 |
| Valerie D Riddle | SVP, Medical Director | 31. Mai 2011 M | 44.436 | 0 | 0 | $0 |
| Joan Fusco | SVP, Operations | 6. Mai 2010 A | 36.730 | 0 | 0 | $0 |
| Christopher C Camut | VP, Gov't Contracts | 21. Januar 2010 F | 46.777 | 0 | 0 | $0 |
| Teri L Lawver | Direktor | 1. Mai 2026 A | · | 0 | 0 | $0 |
| Wayne Pisano | Direktor | 1. Mai 2026 A | 13.498 | 1 | 0 | $20.400 |
| Klaus Schafer | Direktor | 1. Mai 2026 A | 9.179 | 0 | 0 | $0 |
| Philip Hodges | Direktor | 1. Mai 2026 A | 8.731 | 0 | 0 | $0 |
| Catherine A. Sohn | Direktor | 1. Mai 2026 A | 1.500 | 1 | 0 | $2.120 |
| Diane Jorkasky | Direktor | 1. Mai 2026 A | 527 | 1 | 0 | $2.003 |
| John Gill | Direktor | 1. Mai 2026 A | 21.700 | 2 | 0 | $82.622 |
| Mitchel Sayare | Direktor | 1. Mai 2026 A | 26.363 | 0 | 0 | $0 |
| Vipin K Garg | Direktor | 30. Januar 2026 M | 424.519 | 0 | 0 | $0 |
| David Drutz | Direktor | 19. August 2024 M | 55.524 | 0 | 0 | $0 |
| SCHAFFER DERACE L | Direktor | 29. Dezember 2017 P | 589.453 | 0 | 0 | $0 |
| Jeffrey W. Runge | Direktor | 20. Januar 2017 M | 197.700 | 0 | 0 | $0 |
| Steven St Peter | Direktor | 4. Januar 2017 M | 205.004 | 0 | 0 | $0 |
| Eric I Richman | Direktor | 22. November 2016 M | 898.055 | 0 | 0 | $0 |
| Joel Mccleary | Direktor | 31. Dezember 2014 A | 120.167 | 0 | 0 | $0 |
| Brian A Markison | Direktor | 31. Dezember 2014 A | · | 0 | 0 | $0 |
| John Pappajohn | Direktor | 23. Juni 2011 A | 394.044 | 0 | 0 | $0 |
| CAVANAUGH JAMES H | Direktor | 23. Juni 2010 A | · | 0 | 0 | $0 |
| VELOCITY PHARMACEUTICAL HOLDINGS LLC | 10%-Eigentümer | 15. Mai 2020 S | 1.687.250 | 0 | 0 | $0 |
| Truffle Capital S.A.S. | 10%-Eigentümer | 13. Februar 2018 J | 76.700 | 0 | 0 | $0 |
| ANSBERT GADICKE | 10%-Eigentümer | 3. August 2007 A | · | 0 | 0 | $0 |
| Jordan P Karp | · | 3. Dezember 2012 A | 21.929 | 0 | 0 | $0 |
| Matthew P Kinley | · | 3. August 2007 P | 541.000 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 24 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,73% | 119.086 NS | 31. Juli 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,48% | 38.580 SH | 1. Oktober 2026 | Täglich |
| LABU · Direxion Shares ETF Trust | 0,16% | 275.123 NS | 31. Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,15% | 673.707 SH | 11. September 2026 | Täglich |
| IBB · iShares Trust | 0,05% | 1.414.762 SH | 11. September 2026 | Täglich |
| PWS · Pacer Funds Trust | 0,04% | 3.759 NS | 31. Juli 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,04% | 172.834 SH | 19. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,04% | 13.762 SH | 1. Oktober 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 207.080 SH | 1. Oktober 2026 | Täglich |
| IWM · iShares Trust | 0,02% | 5.067.516 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 1.142.675 SH | 19. August 2026 | Täglich |
| RSSL · Global X Funds | 0,02% | 94.969 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 2.235.429 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 569.267 SH | 19. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,00% | 167.692 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 358.632 SH | 11. September 2026 | Täglich |
| DCOR · Dimensional ETF Trust | 0,00% | 8.167 NS | 31. Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 23.537 SH | 3. September 2026 | Täglich |
| DFUS · Dimensional ETF Trust | 0,00% | 25.408 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 9.653 NS | 31. Juli 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 34.439 NS | 31. Juli 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.748.771 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 16.865 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 1.858.292 SH | 11. September 2026 | Täglich |
ALT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 15 Analysten
KAUF
Median-Ziel
$17.00
+521,6%
4 26,7%
Starker Kauf
9 60,0%
Kauf
2 13,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
9 Analysten · 2026-09-30Mittelwert-Ziel $17.11 +525,6%
← Unter allen Zielen
Aktueller Preis $2.73
Tief$11.00
Mittelwert$17.11
Hoch$28.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| ALT | $400M | -3.6 | 105.0% | -214861.0% | -45.6% | · |
| IRWD | $550M | 22.5 | -15.7% | 8.1% | -8.5% | · |
| SGMT | · | -3.7 | · | · | -42.3% | · |
| CTMX | $725M | · | -44.8% | -22.8% | -15.9% | · |
| PRME | $626M | -2.6 | 55.3% | -4342.4% | -221.4% | · |
| ALLO | $314M | -1.6 | -76.8% | · | -59.9% | · |
| MPLT | $773M | -0.9 | · | · | -151.1% | · |
| MNPR | · | · | · | · | · | · |
| CBIO | $327M | -24.2 | -86.7% | -1419.6% | -90.0% | · |
| NGNE | $319M | -4.9 | · | · | -33.6% | · |
| ZURA | · | · | · | · | · | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Hier ist, warum Altimmune Inc. (ALT) als attraktiver Penny Stock erscheint
Yahoo Finance · 5 Monate vor
Altimmune Aktionäre Billigen Alle AGM-Anträge, Genehmigte Aktienanzahl auf 400 Mio. erhöht
Yahoo Finance · 5 Monate, 2 Wochen vor
Insider Buying Report vom Freitag, 10. April: CNXC, ALT
Nasdaq · 5 Monate, 3 Wochen vor
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 12, 2026